Navigation Links
Vion Reports 2008 First Quarter Results
Date:5/5/2008

NEW HAVEN, Conn., May 5 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: VION) today announced financial results for the three-month period ended March 31, 2008.

The Company reported a net loss of $8.2 million, or $1.14 per share, for the three-month period ended March 31, 2008, compared with a net loss of $8.0 million, or $1.20 per share, for the same period in 2007. Weighted-average common shares outstanding for the three months ended March 31, 2008 and 2007 were 7.2 million and 6.6 million, respectively.

Operating expenses were reduced by $679,000 from $7.9 million in the 2007 quarter to $7.2 million in 2008. Interest expense increased by $766,000 over the prior year as the Company's Convertible Senior Notes, issued in February 2007, were outstanding for the entire quarter in 2008.

The Company reported ending the quarter with $55.2 million in cash and cash equivalents, sufficient to fund the Company's operations through the third quarter of 2009 based on the current operating plan. The Company also announced that it will pay the interest payment due August 15, 2008 on its Convertible Senior Notes in cash.

Alan Kessman, Chief Executive Officer, commented, "We continue to work on the New Drug Application (NDA) for Cloretazine(R) (VNP40101M). It remains our plan to file the NDA with the U.S. Food and Drug Administration in 2008."

On February 20, 2008, the Company implemented a one-for-ten reverse split of all outstanding shares of its common stock and a corresponding decrease in the number of shares of authorized common stock. Share and per share amounts contained herein are provided on a post-split basis.

Vion Pharmaceuticals, Inc. is committed to extending the lives and improving th
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. eResearchTechnology Reports First Quarter 2008 Results
2. MannKind Corporation Reports First Quarter Financial Results
3. Verenium Reports Financial Results for the First Quarter 2008
4. ev3 Inc. Reports 2008 First Quarter Financial Results and Revised 2008 Guidance
5. United Therapeutics Reports First Quarter 2008 Financial Results
6. Endocare Reports 2008 First Quarter Financial Results
7. AMICAS Reports Financial Results for the First Quarter Ended March 31, 2008
8. LeMaitre Vascular Reports Q1 2008 Revenue of $11.8 Million, a 20% Increase
9. Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights
10. Neurobiological Technologies Reports Receipt of $2.0 Million Royalty Payment for Quarterly Sales of Memantine
11. Alexion Reports First Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... NY (PRWEB) January 14, 2014 ... coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua is ... marketing proprietary products to serve the wound care ... , In late 2012, Alliqua was restructured with ... the company’s new strategy to become a leading ...
(Date:1/14/2014)... 14, 2014 iLab Solutions, the leader ... as the new Director of Product Strategy. In this ... as well as iLab sub-teams to guide in the ... to ensure that iLab provides the maximum possible benefit ... user-friendly, and high-impact solution in the world. , ...
(Date:1/14/2014)... January 14, 2014 Global Record ... innovative information technology solutions for patients, physicians, the ... stakeholders, announced today the signing of a three-year ... and Drug Administration (FDA). This initiative is ... to patient safety, clinical outcomes, and medication adherence. ...
(Date:1/14/2014)... Kerr Corporation, a leading manufacturer of innovative ... information about dual arch impressions on its dental blog. ... the blog entry serves up a list of tips to ... demonstration by Dr. David Little as he crafts a porcelain ... Advanced Rigid as the dual arch dental impression material ...
Breaking Biology Technology:EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2
... friend, Scott Beth, vice president of procurement at Intuit, has ... economic recession. It is as if the swamp was drained, ... and rusting barrels at the swamp bottom. That is, the ... organizational excess and mismanagement. With the money drained, the trash ...
... People are starting to feel somewhat comfortable with their portfolios ... reality that far too many tech related jobs in the ... pundits are saying in four to five years the US ... deficits and the ever-increasing trade imbalances with countries such as ...
... MILWAUKEE, WI. - Research presented at the Wisconsin Economic ... in Wisconsin shows promise, barriers still exist for the ... presented by the Wisconsin Association for Biomedical Research ... growth industry worldwide - and identified Wisconsin as a ...
Cached Biology Technology:DEMOLetter: Draining the Economic Swamp 2DEMOLetter: Draining the Economic Swamp 3DEMOLetter: Draining the Economic Swamp 4The Next Economy - Market Collapses Drive Long-Term Growth 2Barriers Outlined for Wisconsins Biotech Growth 2Barriers Outlined for Wisconsins Biotech Growth 3
(Date:3/13/2014)... Populations of endangered salmonids are supported by releasing ... catches have continued to decrease. Earlier research has ... in how fish survive in the wild. A ... shows that there are predictable individual differences in ... surroundings and stress tolerance. Furthermore, certain individual differences ...
(Date:3/13/2014)... University of Liverpool have found that tropical grassy areas, ... are under threat as a result of ineffective management. ... Ecology and Evolution , they are often misclassified and ... a detrimental effect on the plants and animals that ... grassy areas cover a greater area than tropical rain ...
(Date:3/13/2014)... only receive physical benefits but also are more productive ... researchers from The University of Texas at Arlington, the ... an assistant professor in the UT Arlington School of ... Workstations: The Effects of Walking while Working on Physical ... journal PLoS One Feb. 20., In the ...
Breaking Biology News(10 mins):Tropical grassy ecosystems under threat, scientists warn 2UT Arlington research says treadmill workstation benefits employees, employers 2
... Atmel(R) Corporation (Nasdaq:,ATML) was recently recognized for ... the 2008 Frost & Sullivan Southeast Asia,Industrial Technologies ... Yee, Vice President of Asian Sales for Atmel, ... team., Frost & Sullivan based its selection ...
... How Southern California tackles the daunting task of ... greenhouse gases is the focus of an all-day conference ... for Sustainable Suburban Development and the Southern California ... Issues and Strategies for Future Progress will be ...
... and the scientific community for access to research data, ... to allow authors to retain the rights to work ... effective May 1, applies to all three Rockefeller University ... of Experimental Medicine and The Journal of General Physiology. ...
Cached Biology News:Atmel Receives Frost & Sullivan's Technology Innovation Award for FingerChip(R) Biometric Sensor 2Atmel Receives Frost & Sullivan's Technology Innovation Award for FingerChip(R) Biometric Sensor 3UC Riverside to host conference on stricter air quality standards for Southern California 2Rockefeller University Press allows authors to retain copyright to their published work 2
PPOX Immunogen: PPOX (AAH02357, 378 a.a. ~ 478 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Rabbit polyclonal to Raf1 ( Abpromise for all tested applications). entrezGeneID: 5894 SwissProtID: P04049...
KRIT1 Immunogen: KRIT1 (NP_004903, 637 a.a. ~ 737 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Sheep polyclonal to hCG beta core fragment ( Abpromise for all tested applications). Antigen: Full length native protein (purified) from human urine. Entrez GeneID: 1082 Swiss Protein ID...
Biology Products: